A veteran banker and former pharma R&D chief are launching a fund that will buy up some of the nearly 300 listed biotechs that have had disappointing clinical trials, returning cash to shareholders and acquiring any valuable intellectual property.
一位資深銀行家與一名前制藥公司研發主管正聯手推出一只基金，計劃收購臨床試驗表現令人失望的近300家上市生物技術公司中的部分企業，將現金返還給股東，并獲取其中有價值的知識產權。
您已閱讀9%（334字），剩余91%（3326字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。